Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene

Vaccine

Volumn 29, Issue 43, 2011, Pages 7444-7455

  Ishikawa, Tomohiro ^a,c   Wang, Gongbo ^a,d   Widman, Douglas G ^a,e   Infante, Ernesto ^a,b   Winkelmann, Evandro R ^a,b   Bourne, Nigel ^a,b   Mason, Peter W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d DUPONT COMPANY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Chimera; Japanese encephalitis; Vaccine

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; NONSTRUCTURAL PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; FEMALE; GENE CONSTRUCT; GENE INSERTION; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; VIRUS GENE;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; CRICETINAE; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; JAPANESE ENCEPHALITIS VACCINES; MICE; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, RNA; VACCINATION; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 80053445726     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.058     Document Type: Article

References (63)

1. Gubler D.J., Kuno G., Markoff L. Flaviviruses. Fields virology 2007, Lippincott-Raven, Philadelphia, PA, USA, pp. 1153-1252. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
2. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004, 10:S98-S109.
3. Oya A., Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 2007, 14:259-268.
4. Hanna J.N., Ritchie S.A., Phillips D.A., Shield J., Bailey M.C., Mackenzie J.S., et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust 1996, 165:256-260.
5. Halstead S.B., Jacobsen J. Japanese Encephalitis vaccines. Vaccines 2008, Saunders, Elsevier, Maryland Heights, MO, USA, pp. 311-352. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
6. Ferguson M., Kurane I., Wimalaratne O., Shin J., Wood D. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 2007, 25:5233-5243.
7. Umbach J.L., Cullen B.R. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev 2009, 23:1151-1164.
8. Sejvar J.J. Acute disseminated encephalomyelitis. Curr Infect Dis Rep 2008, 10:307-314.
9. Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev Vaccines 2009, 8:1501-1511.
10. Schioler K.L., Samuel M., Wai K.L. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007, 18:CD004263.
11. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
12. Stadler K., Allison S.L., Schalich J., Heinz F.X. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997, 71:8475-8481.
13. Heinz F.X. Epitope mapping of flavivirus glycoproteins. Adv Virus Res 1986, 31:103-168.
14. Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 1991, 180:294-305.
15. Kojima A., Yasuda A., Asanuma H., Ishikawa T., Takamizawa A., Yasui K., et al. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J Virol 2003, 77:8745-8755.
16. Konishi E., Pincus S., Paoletti E., Shope R.E., Burrage T., Mason P.W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188:714-720.
17. Konishi E., Fujii A., Mason P.W. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol 2001, 75:2204-2212.
18. Qiao M., Ashok M., Bernard K.A., Palacios G., Zhou Z.H., Lipkin W.I., et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis 2004, 190:2104-2108.
19. Hunt A.R., Cropp C.B., Chang G.J. A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J Virol Methods 2001, 97:133-149.
20. Lin Y.L., Chen L.K., Liao C.L., Yeh C.T., Ma S.H., Chen J.L., et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol 1998, 72:191-200.
21. Volpina O.M., Volkova T.D., Koroev D.O., Ivanov V.T., Ozherelkov S.V., Khoretonenko M.V., et al. A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model. Virus Res 2005, 112:95-99.
22. Chung K.M., Nybakken G.E., Thompson B.S., Engle M.J., Marri A., Fremont D.H., et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 2006, 80:1340-1351.
23. Costa S.M., Paes M.V., Barreto D.F., Pinhao A.T., Barth O.M., Queiroz J.L., et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24:195-205.
24. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 1986, 60:1153-1155.
25. Krishna V.D., Rangappa M., Satchidanandam V. Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol 2009, 83:4766-4777.
26. Kofler R.M., Aberle J.H., Aberle S.W., Allison S.L., Heinz F.X., Mandl C.W. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci U S A 2004, 101:1951-1956.
27. Mason P.W., Shustov A.V., Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 2006, 351:432-443.
28. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26:2762-2771.
29. Chang D.C., Liu W.J., Anraku I., Clark D.C., Pollitt C.C., Suhrbier A., et al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 2008, 26:571-577.
30. Widman D.G., Ishikawa T., Winkelmann E.R., Infante E., Bourne N., Mason P.W., et al. a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 2009, 27:5550-5553.
31. Widman D.G., Ishikawa T., Giavedoni L.D., Hodara V.L., Garza Mde L., Montalbo J.A., et al. Evaluation of RepliVAX WN, a single-cycle Flavivirus vaccine, in a non-human primate model of West Nile Virus infection. Am J Trop Med Hyg 2010, 82:1160-1167.
32. Ishikawa T., Widman D.G., Bourne N., Konishi E., Mason P.W. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine 2008, 26:2772-2781.
33. Suzuki R., Winkelmann E.R., Mason P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 2009, 83:1870-1880.
34. Kimura-Kuroda J., Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988, 141:3606-3610.
35. Gilfoy F.D., Mason P.W. West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J Virol 2007, 81:11148-11158.
36. Bourne N., Scholle F., Silva M.C., Rossi S.L., Dewsbury N., Judy B., et al. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 2007, 81:9100-9108.
37. Higuchi R., Krummel B., Saiki R.K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 1988, 16:7351-7367.
38. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9:741-747.
39. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999, 73:3095-3101.
40. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78:12497-12507.
41. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
42. Whitehead S.S., Hanley K.A., Blaney J.E., Gilmore L.E., Elkins W.R., Murphy B.R. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003, 21:4307-4316.
43. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000, 74:3020-3028.
44. Tan C.H., Yap E.H., Singh M., Deubel V., Chan Y.C. Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus. J Gen Virol 1990, 71:745-749.
45. Henchal E.A., Henchal L.S., Schlesinger J.J. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol 1988, 69:2101-2107.
46. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 1992, 190:454-458.
47. Gao N., Chen W., Zheng Q., Fan D.Y., Zhang J.L., Chen H., et al. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination. Immunol Lett 2010, 129:23-31.
48. Hall R.A., Khromykh A.A., Mackenzie J.M., Scherret J.H., Khromykh T.I., Mackenzie J.S. Loss of dimerisation of the nonstructural protein NS1 of Kunjin virus delays viral replication and reduces virulence in mice, but still allows secretion of NS1. Virology 1999, 264:66-75.
49. Lindenbach B.D., Rice C.M. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol 1997, 71:9608-9617.
50. Lindenbach B.D., Rice C.M. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol 1999, 73:4611-4621.
51. Falgout B., Markoff L. Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum. J Virol 1995, 69:7232-7243.
52. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A 1992, 89:10532-10536.
53. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication. Fields virology 2007, Lippincott-Raven, Philadelphia, PA, USA, pp. 1102-1153. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
54. Mackenzie J.M., Khromykh A.A., Jones M.K., Westaway E.G. Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology 1998, 245:203-215.
55. Shiryaev S.A., Chernov A.V., Aleshin A.E., Shiryaeva T.N., Strongin A.Y. NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus. J Gen Virol 2009, 90:2081-2085.
56. Kanesa-thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000, 19:483-491.
57. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75:7290-7304.
58. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188:1213-1230.
59. Takasaki T., Yabe S., Nerome R., Ito M., Yamada K., Kurane I. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 2003, 21:4514-4518.
60. Goverdhan M.K., Kulkarni A.B., Gupta A.K., Tupe C.D., Rodrigues J.J. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol 1992, 36:277-283.
61. Tesh R.B., Travassos da Rosa A.P., Guzman H., Araujo T.P., Xiao S.Y. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 2002, 8:245-251.
62. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
63. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80:302-311.